%0 Journal Article
%A Fazekas, Tamás
%A Széles, Ádám D
%A Teutsch, Brigitta
%A Csizmarik, Anita
%A Vékony, Bálint
%A Kói, Tamás
%A Ács, Nándor
%A Hegyi, Péter
%A Hadaschik, Boris
%A Nyirády, Péter
%A Szarvas, Tibor
%T Poly (ADP-ribose) Polymerase Inhibitors Have Comparable Efficacy with Platinum Chemotherapy in Patients with BRCA-positive Metastatic Castration-resistant Prostate Cancer. A Systematic Review and Meta-analysis.
%J European urology oncology
%V 7
%N 3
%@ 2588-9311
%C Amsterdam
%I Elsevier
%M DKFZ-2023-01898
%P 365-375
%D 2024
%Z 2024 Jun;7(3):365-375
%X Testing for mutations in Breast Cancer Gene 1/2 (BRCA) has emerged as a novel decision-making tool for clinicians. Patients with metastatic castration-resistant prostate cancer (mCRPC) harboring pathogenic BRCA mutations can benefit from poly (ADP-ribose) polymerase inhibitor (PARPi) and platinum treatments, whereas the impact of the mutation on sensitivity to cabazitaxel and prostate-specific membrane antigen (PSMA)-ligand therapy is currently unknown.To assess the efficacy of PARPi, platinum, cabazitaxel, and PSMA-ligand therapies in BRCA-positive mCRPC.Databases were queried in February 2022. We performed data synthesis by using both proportional and individual patient data. For prostate-specific antigen (PSA) response rate (≥50
%K Ac-PSMA (Other)
%K BRCA (Other)
%K Cabazitaxel (Other)
%K Carboplatin (Other)
%K Cisplatin (Other)
%K DNA repair (Other)
%K Lu-PSMA (Other)
%K Metastatic castration-resistant prostate cancer (Other)
%K Niraparib (Other)
%K Olaparib (Other)
%K Prostate cancer (Other)
%K Prostate-specific membrane antigen (Other)
%K Rucaparib (Other)
%K Talazoparib (Other)
%K Taxane (Other)
%K Veliparib (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:37722977
%R 10.1016/j.euo.2023.09.001
%U https://inrepo02.dkfz.de/record/282906